• 1
    Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979; 241: 20352038.
  • 2
    Tuomilehto J, Rastenyte D, Jousilahti P, et al. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 1996; 27: 210215.
  • 3
    Fujishima M, Kiyohara Y, Kato I, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 1996; 45(Suppl 3): S14S16.
  • 4
    Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis. Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421431.
  • 5
    Stettler C, Allemann S, Juni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006; 152: 2738.
  • 6
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977986.
  • 7
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 8
    Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 25452559.
  • 9
    ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 25602572.
  • 10
    Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129139.
  • 11
    Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008; 31: 21982202.
  • 12
    Wadén J, Forsblom C, Thorn LM, et al. Finnish Diabetic Nephropathy Study Group. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009; 58: 26492655.
  • 13
    Prince CT, Becker DJ, Costacou T, et al. Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 2007; 50: 22802288.
  • 14
    Bouchi R, Babazono T, Nyumura I, et al. Relationship between chronic kidney disease and silent cerebral infarction in patients with type 2 diabetes. Diabet Med 2010; 27: 538543.
  • 15
    Alberti KGMM, Zimmet P, for the WHO Consultation. Definition, diagnosis, and classification of diabetes mellitus and its complications, part 2: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539553.
  • 16
    Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease. Circulation 2006; 113: e436e465.
  • 17
    The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212228.
  • 18
    American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79S83.
  • 19
    Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982992.
  • 20
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 21
    Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: pathway selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005; 1: 100110.
  • 22
    DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 12701287.
  • 23
    Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 13491354.
  • 24
    Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycaemia in patients with type 2 diabetes. JAMA 2006; 295: 16811687.
  • 25
    Gopaul NK, Anggard EE, Mallet AI, et al. Plasma 8-iso-PGF levels are elevated in individuals with non-insulin-dependent diabetes mellitus. FEBS Lett 1995; 368: 225229.
  • 26
    Davì G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin F and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224229.